Blockade of kinin B1 receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance

Diabetes, Obesity and Metabolism

Volumn 14, Issue 3, 2012, Pages 244-253

  Dias, J P ^a   Couture, R ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adipose tissue; Fatty acids; Inflammation; Insulin resistance; Obesity

Indexed keywords

ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE 1; ARACHIDONIC ACID; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; CD68 ANTIGEN; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 1BETA; LEPTIN; LINOLEIC ACID; LINOLEOYL COENZYME A DESATURASE; OLEIC ACID; PALMITOLEIC ACID; SSR 240612; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY FAT; CONTROLLED STUDY; EPIDIDYMIS FAT; FATTY ACID BLOOD LEVEL; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID COMPOSITION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; RETROPERITONEAL FAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84857034781     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01521.x     Document Type: Article

References (57)

1. Regoli D, Nsa AS, Rizzi A, Gobeil FJ. Bradykinin receptors and their antagonists. Eur J Pharmacol 1998; 348: 1-10.
2. Marceau F, Sabourin T, Houle S, et al. Kinin receptors: functional aspects. Int Immunopharmacol 2002; 2: 1729-1739.
3. Couture R, Girolami JP. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 2004; 500: 467-485.
4. Tiffany CW, Burch RM. Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. FEBS Lett 1989; 247: 189-192.
5. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77.
6. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos MM. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004; 143: 803-818.
7. Campos MM, Leal PC, Yunes RA, Calixto JB. Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol Sci 2006; 27: 646-651.
8. Dias JP, Ismael MA, Pilon M, et al. The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol 2007; 152: 280-287.
9. Dias JP, Talbot S, Senecal J, Carayon P, Couture R. Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS One 2010; 5: e12622.
10. El Midaoui A, de Champlain J. Effects of glucose and insulin on the development of oxidative stress and hypertension in animal models of type 1 and type 2 diabetes. J Hypertens 2005; 23: 581-588.
11. Ismael MA, Talbot S, Carbonneau CL, Beausejour CM, Couture R. Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance. Eur J Pharmacol 2008; 589: 66-72.
12. Lungu C, Dias JP, Franca CE, et al. Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides 2007; 41: 375-387.
13. Collison KS, Zaidi MZ, Saleh SM, et al. Effect of trans-fat, fructose and monosodium glutamate feeding on feline weight gain, adiposity, insulin sensitivity, adipokine and lipid profile. Br J Nutr 2011; 24: 1-10.
14. Meirelles CJ, Oliveira LA, Jordao AA, Navarro AM. Metabolic effects of the ingestion of different fructose sources in rats. Exp Clin Endocrinol Diabetes 2011; 119: 218-220.
15. Barnard RJ, Roberts CK, Varon SM, Berger JJ. Diet-induced insulin resistance precedes other aspects of the metabolic syndrome. J Appl Physiol 1998; 84: 1311-1315.
16. Coelho MS, Lopes KL, Freitas RA, et al. High sucrose intake in rats is associated with increased ACE2 and angiotensin-(1-7) levels in the adipose tissue. Regul Pept 2010; 162: 61-67.
17. Fukuchi S, Hamaguchi K, Seike M, Himeno K, Sakata T, Yoshimatsu H. Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats. Exp Biol Med (Maywood) 2004; 229: 486-493.
18. Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia 1994; 37: 1044-1050.
19. Vessby B. Dietary fat and insulin action in humans. Br J Nutr 2000; 83(Suppl. 1): S91-S96.
20. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
21. Forsythe LK, Wallace JM, Livingstone MB. Obesity and inflammation: the effects of weight loss. Nutr Res Rev 2008; 21: 117-133.
22. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 2008; 114: 183-194.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
24. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986; 27: 114-120.
25. Lepage G, Levy E, Ronco N, Smith L, Galeano N, Roy CC. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J Lipid Res 1989; 30: 1483-1490.
26. Gomez-Ruiz A, Milagro FI, Campion J, Martinez JA, de Miquel C. High-fat diet feeding alters metabolic response to fasting/non fasting conditions. Effect on caveolin expression and insulin signalling. Lipids Health Dis 2011; 10: 55.
27. Pouliot M, Hetu S, Lahjouji K, Couture R, Vaucher E. Modulation of retinal blood flow by kinin B(1) receptor in Streptozotocin-diabetic rats. Exp Eye Res 2011; 92: 482-489.
28. Talbot S, Chahmi E, Dias JP, Couture R. Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy. J Neuroinflammation 2010; 7: 36.
29. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
30. Gil-Campos M, del Carmen Ramírez-Tortosa M, Larque E, et al. Metabolic syndrome affects fatty acid composition of plasma lipids in obese prepubertal children. Lipids 2008; 43: 723-732.
31. Mozaffarian D, Cao H, King IB, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med 2010; 153: 790-799.
32. Tataranni PA. Metabolic syndrome: is there a pathophysiological common denominator? World Rev Nutr Diet 2005; 94: 75-83.
33. Ondrak KS, McMurray RG, Hackney AC, Harrell JS. Interrelationships among changes in leptin, insulin, cortisol and growth hormone and weight status in youth. J Clin Res Pediatr Endocrinol 2011; 3: 22-28.
34. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
35. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
36. White MF. Insulin signaling in health and disease. Science 2003; 302: 1710-1711.
37. Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004; 34: 641-642.
38. Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011; 96: E146-E150.
39. Pakiz B, Flatt SW, Bardwell WA, Rock CL, Mills PJ. Effects of a weight loss intervention on body mass, fitness, and inflammatory biomarkers in overweight or obese breast cancer survivors. Int J Behav Med 2011; 18: 333-341.
40. Andersson K, Gaudiot N, Ribiere C, Elizalde M, Giudicelli Y, Arner P. A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo. Br J Pharmacol 1999; 126: 1639-1645.
41. Engeli S, Janke J, Gorzelniak K, et al. Regulation of the nitric oxide system in human adipose tissue. J Lipid Res 2004; 45: 1640-1648.
42. Dallaire P, Bellmann K, Laplante M, et al. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. Diabetes 2008; 57: 1999-2011.
43. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001; 7: 1138-1143.
44. Sugita H, Fujimoto M, Yasukawa T, et al. Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 2005; 280: 14203-14211.
45. Bouthillier J, Deblois D, Marceau F. Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo. Br J Pharmacol 1987; 92: 257-264.
46. Klein J, Gonzalez J, Duchene J, et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 2009; 23: 134-142.
47. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
48. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007; 56: 16-23.
49. Costa Rosa LF, Safi DA, Cury Y, Curi R. The effect of insulin on macrophage metabolism and function. Cell Biochem Funct 1996; 14: 33-42.
50. Brechter AB, Persson E, Lundgren I, Lerner UH. Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases. Bone 2008; 43: 72-83.
51. Mori MA, Araujo RC, Reis FC, et al. Kinin B1 receptor deficiency leads to leptin hypersensitivity and resistance to obesity. Diabetes 2008; 57: 1491-1500.
52. Russell JC, Kelly SE, Diane A, et al. Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. Am J Physiol Gastrointest Liver Physiol 2010; 299: G507-G516.
53. Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H. Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp Anim 2000; 49: 239-249.
54. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12: 962-971.
55. Amundson DE, Djurkovic S, Matwiyoff GN. The obesity paradox. Crit Care Clin 2010; 26: 583-596.
56. Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B. Usage, risk, and benefit of weight-loss drugs in primary care. J Obes 2011; 2011: 459263.
57. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-1486.